close Icon

Eliminate C Australia- Impact of hepatitis C cure on hepatitis C related liver morbidity and mortality

Introduction of universal access to hepatitis C curative treatment in Australia has revolutionised care for people living with hepatitis C.

However, the impact of hepatitis C cure on liver cirrhosis and hepatocellular carcinoma incidence and survival are not well described in Australia.

Primary Objectives

  1. To describe the impact of universal access to hepatitis C treatment on incidence of hepatitis C-related cirrhosis
  2. To describe the impact of universal access to hepatitis C treatment on mortality from hepatitis C-related cirrhosis
  3. To describe the impact of universal access to hepatitis C treatment on incidence of hepatitis C-related liver cancer
  4. To describe the impact of universal access to hepatitis C treatment on mortality from hepatitis C-related liver cancer
  5. To determine the proportion of people with hepatitis C-related cirrhosis who are linked to specialist care
  6. To determine the proportion of people with hepatitis C related cirrhosis who are enrolled in liver cancer surveillance
  7. To determine the impact of hepatitis C treatment availability in community settings on timely referral of people with cirrhosis to specialist care and liver cancer surveillance

Secondary Objectives

  1. To determine factors associated with linkage of people with cirrhosis to specialist care
  2. To determine factors associated with linkage of people with cirrhosis to liver cancer surveillance 

2021-2027

This is a longitudinal cohort study with data linkage, combining several datasets from the HOMER2, PRECISE and ANZLITR registries and state hospital admissions, emergency admissions and Victorian Cancer registry databases.

Understanding the impact of hepatitis C related health policies on clinical outcomes and mortality is essential to support ongoing investment in hepatitis C elimination activities.

It is also vital to understand potential gaps and barriers to people with hepatitis C cirrhosis receiving timely best-practice care, referral to specialist services and enrolment in liver cancer surveillance.

Associate Professor Jessica Howell

Contact Associate Professor Jessica Howell for more information about this project. 

EMAIL

Funding
Partners

  • NHMRC Program grant
  • Ramsay program grant
  • Avant Foundation grant

Partners +
Collaborators

  • EC Australia collaborators
  • St Vincent’s Hospital Melbourne
  • Melbourne Liver Group
  • ANZLITR registry consortium
  • Alfred Health
  • Monash Health
  • Eastern health
  • Western Health
  • Melbourne Health
  • Northern Health
  • Austin Health
  • University of Melbourne